FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1835240468> ?p ?o ?g. }

• W1835240468 endingPage "549" @default.
• W1835240468 startingPage "539" @default.
• W1835240468 abstract "BACKGROUND AND METHODS Here, we report on the evaluation of the diagnostic performance of ejaculate‐derived PCA3, Hepsin, and miRNAs to complement serum PSA to detect prostate cancer. cDNA was prepared from 152 candidate specimens following RNA isolation and amplification for PSA, PCA3 and Hepsin qPCR, with 66 having adequate RNA for all three assays. Small RNA sequencing and examination of PCa‐associated miRNAs miR‐200b, miR‐200c, miR‐375 and miR‐125b was performed on 20 specimens. We compared findings from prostate biopsies using D'Amico and PRIAS classifications and in relation to whole gland histopathology following radical prostatectomy. Multivariate logistic regression modeling and clinical risk (incorporating standard clinicopathological variables) were performed for all ejaculate‐based markers. RESULTS While Hepsin alone was not of predictive value, the Hepsin:PCA3 ratio together with serum PSA, expressed as a univariate composite score based on multivariate logistic regression, was shown to be a better predictor than PSA alone of prostate cancer status (AUC 0.724 vs. 0.676) and risk, using D'Amico (AUC 0.701 vs. 0.680) and PRIAS (AUC 0.679 vs. 0.659) risk stratification criteria as classified using prostate biopsies. It was also possible to analyse a subgroup of patients for miRNA expression with miR‐200c (AUC 0.788) and miR‐375 (AUC 0.758) showing best single marker performance, while a combination of serum PSA, miR‐200c, and miR‐125b further improved prediction for prostate cancer status when compared to PSA alone determined by biopsy (AUC 0.869 vs. 0.672; P < 0.05), and risk (D'Amico/PRIAS) as well as by radical prostatectomy histology (AUC 0.809 vs. 0.690). For prostate cancer status by biopsy, at a sensitivity of 90%, the specificity of the test increased from 11% for PSA alone to 67% for a combination of PSA, miR‐200c, and miR‐125b. CONCLUSIONS These results show that use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies. Prostate 75: 539–549, 2015 . © 2015 Wiley Periodicals, Inc." @default.
• W1835240468 created "2016-06-24" @default.
• W1835240468 creator A5013189928 @default.
• W1835240468 creator A5018718250 @default.
• W1835240468 creator A5032243347 @default.
• W1835240468 creator A5034554281 @default.
• W1835240468 creator A5045527532 @default.
• W1835240468 creator A5050374698 @default.
• W1835240468 creator A5058589405 @default.
• W1835240468 creator A5062462797 @default.
• W1835240468 creator A5062735599 @default.
• W1835240468 creator A5064622840 @default.
• W1835240468 creator A5068382557 @default.
• W1835240468 creator A5086310893 @default.
• W1835240468 creator A5091297318 @default.
• W1835240468 date "2015-01-18" @default.
• W1835240468 modified "2023-10-16" @default.
• W1835240468 title "Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer" @default.
• W1835240468 cites W1895190198 @default.
• W1835240468 cites W1951171351 @default.
• W1835240468 cites W1972633570 @default.
• W1835240468 cites W1978177793 @default.
• W1835240468 cites W1979349240 @default.
• W1835240468 cites W1979940427 @default.
• W1835240468 cites W1992135184 @default.
• W1835240468 cites W2003396159 @default.
• W1835240468 cites W2009418018 @default.
• W1835240468 cites W2021443328 @default.
• W1835240468 cites W2028371694 @default.
• W1835240468 cites W2030687108 @default.
• W1835240468 cites W2036186427 @default.
• W1835240468 cites W2038289366 @default.
• W1835240468 cites W2050735593 @default.
• W1835240468 cites W2054139665 @default.
• W1835240468 cites W2059684966 @default.
• W1835240468 cites W2067356373 @default.
• W1835240468 cites W2079901905 @default.
• W1835240468 cites W2107190872 @default.
• W1835240468 cites W2108244474 @default.
• W1835240468 cites W2112044462 @default.
• W1835240468 cites W2117792530 @default.
• W1835240468 cites W2120719882 @default.
• W1835240468 cites W2121158863 @default.
• W1835240468 cites W2132803044 @default.
• W1835240468 cites W2140220265 @default.
• W1835240468 cites W2144807876 @default.
• W1835240468 cites W2145655945 @default.
• W1835240468 cites W2150904349 @default.
• W1835240468 cites W2169385858 @default.
• W1835240468 cites W2326212913 @default.
• W1835240468 cites W2328176404 @default.
• W1835240468 cites W4255804705 @default.
• W1835240468 doi "https://doi.org/10.1002/pros.22942" @default.
• W1835240468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25597828" @default.
• W1835240468 hasPublicationYear "2015" @default.
• W1835240468 type Work @default.
• W1835240468 sameAs 1835240468 @default.
• W1835240468 citedByCount "39" @default.
• W1835240468 countsByYear W18352404682015 @default.
• W1835240468 countsByYear W18352404682016 @default.
• W1835240468 countsByYear W18352404682017 @default.
• W1835240468 countsByYear W18352404682018 @default.
• W1835240468 countsByYear W18352404682019 @default.
• W1835240468 countsByYear W18352404682020 @default.
• W1835240468 countsByYear W18352404682021 @default.
• W1835240468 countsByYear W18352404682022 @default.
• W1835240468 countsByYear W18352404682023 @default.
• W1835240468 crossrefType "journal-article" @default.
• W1835240468 hasAuthorship W1835240468A5013189928 @default.
• W1835240468 hasAuthorship W1835240468A5018718250 @default.
• W1835240468 hasAuthorship W1835240468A5032243347 @default.
• W1835240468 hasAuthorship W1835240468A5034554281 @default.
• W1835240468 hasAuthorship W1835240468A5045527532 @default.
• W1835240468 hasAuthorship W1835240468A5050374698 @default.
• W1835240468 hasAuthorship W1835240468A5058589405 @default.
• W1835240468 hasAuthorship W1835240468A5062462797 @default.
• W1835240468 hasAuthorship W1835240468A5062735599 @default.
• W1835240468 hasAuthorship W1835240468A5064622840 @default.
• W1835240468 hasAuthorship W1835240468A5068382557 @default.
• W1835240468 hasAuthorship W1835240468A5086310893 @default.
• W1835240468 hasAuthorship W1835240468A5091297318 @default.
• W1835240468 hasConcept C121608353 @default.
• W1835240468 hasConcept C126322002 @default.
• W1835240468 hasConcept C143998085 @default.
• W1835240468 hasConcept C151956035 @default.
• W1835240468 hasConcept C2775934546 @default.
• W1835240468 hasConcept C2776235491 @default.
• W1835240468 hasConcept C2779466945 @default.
• W1835240468 hasConcept C2780192828 @default.
• W1835240468 hasConcept C2781217009 @default.
• W1835240468 hasConcept C29456083 @default.
• W1835240468 hasConcept C71924100 @default.
• W1835240468 hasConcept C87874733 @default.
• W1835240468 hasConceptScore W1835240468C121608353 @default.
• W1835240468 hasConceptScore W1835240468C126322002 @default.
• W1835240468 hasConceptScore W1835240468C143998085 @default.
• W1835240468 hasConceptScore W1835240468C151956035 @default.
• W1835240468 hasConceptScore W1835240468C2775934546 @default.

• next